Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Rollema

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Neurochemistry International|November 9, 2010
Effect of co-administration of varenicline and antidepressants on extracellular monoamine concentrations in rat prefrontal cortexHans Rollema, Gary G Wilson, Theodore C Lee, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 27, 2016
Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain ConcentrationsThomas I F H Cremers, Gunnar Flik, Joost H A Folgering, et al.
Clinical Pharmacokinetics|November 9, 2010
A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessationHélène M Faessel, R Scott Obach, Hans Rollema, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 13, 2006
Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effectsKaren L Houseknecht, Alan S Robertson, William Zavadoski, et al.
Drugs of Today (Barcelona, Spain : 1998)|March 14, 2007
Varenicline: new treatment with efficacy in smoking cessationVictor I Reus, R Scott Obach, Jotham W Coe, et al.
Trends in Pharmacological Sciences|June 19, 2007
Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessationHans Rollema, Jotham W Coe, Leslie K Chambers, et al.
Dementia and Geriatric Cognitive Disorders|November 20, 2013
Phase II crossover trial of varenicline in mild-to-moderate Alzheimer's diseaseSeong Yoon Kim, Seong Hye Choi, Hans Rollema, et al.
European Journal of Pharmacology|January 27, 2009
Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effectHans Rollema, Victor Guanowsky, Yann S Mineur, et al.
Current Medical Research and Opinion|February 14, 2020
Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populationsSerena Tonstad, Cynthia Arons, Hans Rollema, et al.
Neuropharmacology|May 4, 2013
Therapeutic doses of antidepressants are projected not to inhibit human α4β2 nicotinic acetylcholine receptorsMark L Weber, Corry M Hofland, Christopher L Shaffer, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Neurochemistry International|November 9, 2010
Effect of co-administration of varenicline and antidepressants on extracellular monoamine concentrations in rat prefrontal cortexHans Rollema, Gary G Wilson, Theodore C Lee, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 27, 2016
Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain ConcentrationsThomas I F H Cremers, Gunnar Flik, Joost H A Folgering, et al.
Clinical Pharmacokinetics|November 9, 2010
A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessationHélène M Faessel, R Scott Obach, Hans Rollema, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 13, 2006
Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effectsKaren L Houseknecht, Alan S Robertson, William Zavadoski, et al.
Drugs of Today (Barcelona, Spain : 1998)|March 14, 2007
Varenicline: new treatment with efficacy in smoking cessationVictor I Reus, R Scott Obach, Jotham W Coe, et al.
Trends in Pharmacological Sciences|June 19, 2007
Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessationHans Rollema, Jotham W Coe, Leslie K Chambers, et al.
Dementia and Geriatric Cognitive Disorders|November 20, 2013
Phase II crossover trial of varenicline in mild-to-moderate Alzheimer's diseaseSeong Yoon Kim, Seong Hye Choi, Hans Rollema, et al.
European Journal of Pharmacology|January 27, 2009
Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effectHans Rollema, Victor Guanowsky, Yann S Mineur, et al.
Current Medical Research and Opinion|February 14, 2020
Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populationsSerena Tonstad, Cynthia Arons, Hans Rollema, et al.
Neuropharmacology|May 4, 2013
Therapeutic doses of antidepressants are projected not to inhibit human α4β2 nicotinic acetylcholine receptorsMark L Weber, Corry M Hofland, Christopher L Shaffer, et al.
Pageof 4